Churbz: That is why I see up listing occuring around Feb. 1, 2015. We will have started Lympro commercialization, Elto trial will have started, and we'll have one or two MANF orphans by then. I think that would put us in the .20 to .30 cent range. A 1:15 RS would put us on NASDAQ and I think we would do fine.